沙利度胺、低剂量地西他滨联合治疗骨髓增生异常综合征的临床效果评价  

Clinical Effect Evaluation of Combination Therapy of Thalidomide and Low-Dose Decitabine in Treatment of Myelodysplastic Syndrome

作　　者：宋丽丽 郜晓 许纯 朱凯 SONG Lili;GAO Xiao;XU Chun;ZHU Kai(Department of Oncology and Hematology,Zhangjiagang City Traditional Chinese Medicine Hospital,Zhangjiagang,Jiangsu 215600)

机构地区：[1]张家港市中医医院肿瘤血液病科,江苏张家港215600

出　　处：《智慧健康》2024年第19期71-73,共3页Smart Healthcare

摘　　要：目的分析沙利度胺、低剂量地西他滨联合治疗骨髓增生异常综合征的临床效果。方法选取2018年1月—2022年12月在本院就诊的90例骨髓增生异常综合征患者作为研究对象,并依据不同治疗方法将其分为观察组和对照组,每组45例。其中,对照组接受沙利度胺治疗,观察组应用沙利度胺、低剂量地西他滨结合治疗,治疗后比较治疗总有效率和血象指标。结果观察组的治疗效果在完全缓解(CR)和总体缓解率(ORR)方面明显优于对照组,差异有统计学意义(P<0.05)。观察组的治疗后血象相关指标显著高于对照组值,差异有统计学意义(P<0.05)。结论沙利度胺和低剂量地西他滨的联合治疗在改善MDS患者的生存率和疾病控制率方面显示出潜力。Objective To analyze clinical effect of thalidomide combined with low-dose dexamethasone in treatment of myelodysplastic syndrome.Methods The paper chose 90 patients with myelodysplastic syndrome in the hospital from January 2018 to December 2022 as study subjects,evaluated and compared total effective rate of treatment and blood count indicators comprehensively.Results Treatment effect in observation group was significantly better than control group in terms of complete response(CR)and overall response rate(ORR),with statistical significance(P<0.05).Post-treatment value in observation group was significantly higher than control group,difference was statistically significant,indicating treatment in observation group was significant better,(P<0.05).Conclusion Combination of thalidomide and lowdose dexamethasone has potential in improving survival and disease control rates of MDS patients.

关 键 词：骨髓增生异常综合征 地西他滨 病态造血 

分 类 号：R551.3[医药卫生—血液循环系统疾病]